A Study of Infection Profile and Its Association with Induction Outcomes in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia (ALL) at a Tertiary Cancer Center in Northeast India

Gelijkaardige items

• Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
  door: Jing Lu, et al.
  Gepubliceerd in: (2024-09-01)
• Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD
  door: Jing Lu, et al.
  Gepubliceerd in: (2025-02-01)
• Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial
  door: Sergei Nikolaevich Bondarenko, et al.
  Gepubliceerd in: (2019-04-01)
• The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia
  door: Xiaoxia Wu, et al.
  Gepubliceerd in: (2024-09-01)
• Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
  door: Sandrine Niyongere, et al.
  Gepubliceerd in: (2020-06-01)